Uni-Bio Science Group Limited Announces Extraordinary General Meeting with Major Share Option Scheme Changes

Key Upcoming Event: Extraordinary General Meeting (EGM)

Uni-Bio Science Group Limited (Stock Code: 0690) has issued a notice to convene an Extraordinary General Meeting (EGM) on Tuesday, 26 May 2026, at 11:00 a.m. The meeting will take place at Unit 502, 5/F, No. 20 Science Park East Avenue, Hong Kong Science Park, Shatin, New Territories, Hong Kong.

Key Proposals on the Table

1. Adoption of a New Share Option Scheme:
   • The Company is seeking shareholder approval to adopt a new share option scheme (“New Share Option Scheme”).
   • The scheme is subject to the Stock Exchange of Hong Kong granting approval for the listing and dealing of new shares to be issued upon exercise of options.
   • The maximum number of shares that may be issued under the scheme is capped at 10% of the company’s total issued shares (excluding treasury shares) as at the date of the resolution (the “Scheme Mandate Limit”).
   • The Board (or an authorized committee) will be empowered to administer, modify, and amend the scheme within the prescribed rules, issue shares under the scheme, and take necessary actions to implement it.
   • This could have a potentially significant dilutive impact if the full mandate is exercised, which investors should consider as it may affect share value.
2. Termination of Existing Share Option Scheme:
   • The EGM will also vote on the termination of the existing share option scheme, which was adopted on 26 September 2016, conditional upon the new scheme’s approval and adoption.
   • Importantly, any outstanding options already granted under the existing scheme will remain valid and unaffected.
3. Approval of Service Provider Sublimit:
   • The EGM will consider a specific sublimit within the new share option scheme, allowing up to 1% of shares in issue (excluding treasury shares) as at the date of approval to be granted to service providers.
   • This is a distinct allocation under the new scheme, which could be used to incentivize third-party service providers, potentially affecting future share issuance and dilution.

Important Shareholder Information

• Register Closure: The register of members will be closed from Wednesday, 20 May 2026 to Tuesday, 26 May 2026 (both days inclusive). Shareholders must ensure any share transfers are registered by 4:30 p.m. on Tuesday, 19 May 2026 to be eligible to attend and vote at the EGM.
• Proxy Arrangements: Shareholders entitled to attend and vote may appoint proxies. Multiple proxies are allowed for those holding more than one share. Proxy forms must reach the Company’s Hong Kong registrar by 11:00 a.m. on Friday, 22 May 2026.
• Voting Method: All resolutions will be decided by poll, as required by the Stock Exchange listing rules.
• Board Composition: The Board currently consists of four executive directors (including Chairman Mr. Kingsley Leung), two non-executive directors, and three independent non-executive directors.

Potential Price-Sensitive Implications

• Significant Potential Dilution: The approval of the new share option scheme and its 10% mandate limit, plus an additional 1% for service providers, could result in substantial share dilution if fully utilized. This is a key factor that could impact the share price.
• Termination of Old Scheme: The winding up of the prior scheme consolidates future share option grants under the new, updated regime, potentially aligning incentives more closely with current business strategy.
• Enhanced Flexibility and Attraction: The new scheme may provide Uni-Bio Science Group with greater flexibility to attract and retain talent and incentivize third-party service providers, which could be viewed positively by the market if seen as supporting future growth.

Conclusion

The proposals to be voted on at the upcoming EGM represent potentially price-sensitive developments for Uni-Bio Science Group Limited. The approval of the new share option scheme, the associated dilution limits, and the termination of the old scheme are all significant items of corporate governance and capital management. Investors should watch closely for the outcome of the EGM, as these measures could influence both the capital structure and incentive alignment within the company, with direct implications for share value and market perception.

Disclaimer: This article is a summary and interpretation of the official EGM notice issued by Uni-Bio Science Group Limited. It does not constitute investment advice. Investors should review the full official documents and seek professional advice before making investment decisions. The author and publisher take no responsibility for any actions taken based on this article.

View UNI-BIO GROUP Historical chart here